We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 15 of 125 for:    fibromyalgia | Recruiting, Not yet recruiting, Available Studies

Endogenous Opioid Systems and Symptom Change in Fibromyalgia

This study is not yet open for participant recruitment.
Verified August 2017 by Jon-Kar Zubieta, University of Utah
Sponsor:
ClinicalTrials.gov Identifier:
NCT02866461
First Posted: August 15, 2016
Last Update Posted: August 29, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Jon-Kar Zubieta, University of Utah
  Purpose
This study is designed to study brain mechanisms associated with symptoms and severity of Fibromyalgia. This will be accomplished by relating results from PET scans to self-reported and objective measures of disease severity.

Condition Intervention
Fibromyalgia Other: No treatment

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: Endogenous Opioid Systems and Symptom Change in Fibromyalgia

Resource links provided by NLM:


Further study details as provided by Jon-Kar Zubieta, University of Utah:

Primary Outcome Measures:
  • change in mu opioid-mediated neurotransmission [ Time Frame: Change from baseline at 6 weeks ]
    assessed via PET scanning


Secondary Outcome Measures:
  • change in Biomarkers of pain response [ Time Frame: Change from baseline at 6 weeks ]
    serum cortisol

  • change in Biomarkers of pain response [ Time Frame: Change from 8 weeks at 14 weeks ]
    serum cortisol

  • change in Pain [ Time Frame: Change from baseline at 6 weeks ]
    assessed via questionnaire

  • change in Pain [ Time Frame: Change from 8 weeks at 14 weeks ]
    assessed via questionnaire

  • change in mu opioid-mediated neurotransmission [ Time Frame: Change from 8 weeks at 14 weeks ]
    assessed via PET scanning


Biospecimen Retention:   Samples With DNA
Blood will be sampled at baseline to test for genes that may be associated with the function of the chemical signals between nerve cells, function of hormones, and symptoms. The genetic portion of the study is optional.

Estimated Enrollment: 80
Anticipated Study Start Date: October 2017
Estimated Study Completion Date: August 2019
Estimated Primary Completion Date: August 2019 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Fibromyalgia
No treatment
Other: No treatment
Observation

Detailed Description:

The purpose of this study is to examine µ-opioid receptor (µOR)-mediated neurotransmission in patients diagnosed with persistent pain, fibromyalgia (FM), and its relationship with pain and affect measures. µOR activation is expected to take place in the following brain regions: rostral and dorsal anterior cingulate (rACC, dACC), orbitofrontal cortex (OFC), thalamus (THA), nucleus accumbens (NAC), amygdala (AMY), periaqueductal gray (PAG). Greater regional activation is expected to be associated with improvements in clinical pain ratings and affective state.

The endogenous opioid system and µ-opioid receptors (µORs) play a central role in the regulation of pain, the pathophysiology of chronic pain syndromes, mood and emotion; this system is dysregulated in persistent pain syndromes. A substantial body of literature addressing these mechanisms has been developed in our laboratory, including recent data on the cognitive and molecular mechanisms associated with reductions in pain, as well as trait personality and genetic predictors of emotional effects in the context of pain.

Eighty individuals who have been diagnosed with FM and who fit the inclusion and exclusion criteria will be enrolled in this 14-week protocol. An initial visit for informed consent procedures and baseline characterization will then be scheduled, as well as the visits for positron emission tomography (PET) and magnetic resonance imaging (MRI) procedures. Subjects will return for testing after 6 and 14 weeks.

Volunteers will undergo imaging with structural and functional MRI and PET with [11C]carfentanil to determine baseline µOR non-displaceable binding potential (BPND) and changes in those BPND measures coinciding with symptom severity at the time of scanning.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Individuals diagnosed with Fibromyalgia
Criteria

Inclusion Criteria:

  • Have met American College of Rheumatology (ACR) criteria for fibromyalgia for at least 1 year;
  • Willing to limit introduction of new treatments during the study;
  • Use of sleep aids no more than twice per week
  • 18-55 years of age
  • right handed
  • capable of providing written informed consent

Exclusion Criteria:

  • concurrent untreated medical illnesses, autoimmune, or inflammatory disease;
  • Routine daily use of narcotic analgesics or history of substance abuse;
  • Concurrent participation in other therapeutic trials;
  • Pregnancy/ nursing;
  • Ongoing psychiatric illness;
  • Contraindications to PET or MRI methods;
  • Impairments that would prevent completion of the study protocol;
  • Use of sleep aids at frequency of more that twice per week;
  • Allergy to fentanyl
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02866461


Contacts
Contact: Andrea White, PhD 801-587-1288 utahneuroimagelab@gmail.com
Contact: Jon-Kar Zubieta, MD, PhD 801-742-1517 utahneuroimagelab@gmail.com

Sponsors and Collaborators
University of Utah
Investigators
Principal Investigator: Jon-Kar Zubieta, MD, PhD University of Utah
  More Information

Publications:

Responsible Party: Jon-Kar Zubieta, Principal Investigator, University of Utah
ClinicalTrials.gov Identifier: NCT02866461     History of Changes
Other Study ID Numbers: R01 3589819
First Submitted: March 22, 2016
First Posted: August 15, 2016
Last Update Posted: August 29, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Fibromyalgia
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases
Endorphins
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs